Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels

Objective: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID- 19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturer's instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward. According to Roc analysis, 333.1 ng/L adropin had a specificity of 0.8167 (95%, 0.6956-0.9048) and a sensitivity of 0.6522 (95%, 0.4273-0.8362). Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.